Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.
Allogeneic stem cell transplantation
Clinical trial
Cord blood
Ex vivo expansion
Long-term follow-up
Journal
Transplantation and cellular therapy
ISSN: 2666-6367
Titre abrégé: Transplant Cell Ther
Pays: United States
ID NLM: 101774629
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
04
01
2023
revised:
30
01
2023
accepted:
31
01
2023
pmc-release:
01
05
2024
medline:
1
5
2023
pubmed:
13
2
2023
entrez:
12
2
2023
Statut:
ppublish
Résumé
Omidubicel is an umbilical cord blood (UCB)-derived ex vivo-expanded cellular therapy product that has demonstrated faster engraftment and fewer infections compared with unmanipulated UCB in allogeneic hematopoietic cell transplantation. Although the early benefits of omidubicel have been established, long-term outcomes remain unknown. We report on a planned pooled analysis of 5 multicenter clinical trials including 105 patients with hematologic malignancies or sickle cell hemoglobinopathy who underwent omidubicel transplantation at 26 academic transplantation centers worldwide. With a median follow-up of 22 months (range, .3 to 122 months), the 3-year estimated overall survival and disease-free survival were 62.5% and 54.0%, respectively. With up to 10 years of follow-up, omidubicel showed durable trilineage hematopoiesis. Serial quantitative assessments of CD3
Identifiants
pubmed: 36775201
pii: S2666-6367(23)01071-0
doi: 10.1016/j.jtct.2023.01.031
pmc: PMC10149622
mid: NIHMS1882086
pii:
doi:
Types de publication
Meta-Analysis
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
338.e1-338.e6Subventions
Organisme : NHLBI NIH HHS
ID : T32 HL007057
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
Références
Blood Adv. 2020 Feb 25;4(4):789-792
pubmed: 32097457
Nature. 2022 Feb;602(7895):162-168
pubmed: 35058638
N Engl J Med. 2012 Dec 13;367(24):2305-15
pubmed: 23234514
Br J Haematol. 2014 Jul;166(2):209-12
pubmed: 24661075
J Clin Oncol. 2019 Feb 10;37(5):367-374
pubmed: 30523748
Blood. 2011 Jun 9;117(23):6083-90
pubmed: 21436068
Blood. 2021 Oct 21;138(16):1429-1440
pubmed: 34157093
Curr Opin Hematol. 2016 Nov;23(6):524-529
pubmed: 27496639
Am J Clin Pathol. 2011 Apr;135(4):525-40
pubmed: 21411775
Stem Cell Rev Rep. 2020 Aug;16(4):628-638
pubmed: 32424674
N Engl J Med. 2014 Jul 24;371(4):339-48
pubmed: 25054717
Blood. 2015 May 7;125(19):2885-92
pubmed: 25778529
Blood. 2012 Nov 22;120(22):4285-91
pubmed: 22955919
Blood Adv. 2020 Feb 25;4(4):784-788
pubmed: 32097458
Lancet Haematol. 2020 Feb;7(2):e134-e145
pubmed: 31704264
Exp Hematol. 2012 Apr;40(4):342-55.e1
pubmed: 22198152
J Clin Invest. 2014 Jul;124(7):3121-8
pubmed: 24911148
Cell Stem Cell. 2016 Jan 7;18(1):144-55
pubmed: 26669897
Biol Blood Marrow Transplant. 2010 Jul;16(7):1025-31
pubmed: 20178854
Nat Med. 2010 Feb;16(2):232-6
pubmed: 20081862
Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8242-7
pubmed: 12048236
Bone Marrow Transplant. 2009 Nov;44(10):673-81
pubmed: 19802023
Cytotherapy. 2007;9(8):727-8
pubmed: 17917889
N Engl J Med. 2012 Oct 18;367(16):1487-96
pubmed: 23075175
Transplant Cell Ther. 2023 Jan;29(1):52.e1-52.e9
pubmed: 36179986
Blood Adv. 2021 Feb 9;5(3):843-852
pubmed: 33560399